Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 7:36 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | ORBIMED ADVISORS LLC | 11,494,437 6.7% | 1,165,788 (+11.29%) | View |
| 2024-02-14 4:44 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | ACORN BIOVENTURES L.P. | 17,755,869 9.99% | 17,755,869 (New Position) | View |
| 2024-02-14 4:32 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | Lincoln Park Capital Fund LLC | 1,600,136 0.947% | -209,951 (-11.60%) | View |
| 2024-02-13 6:55 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | Bain Capital Life Sciences Fund L.P. | 16,915,784 11% | 4,713,274 (+38.63%) | View |
| 2024-02-07 5:09 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | BlackRock Inc. BLK | 8,160,747 4.9% | -256,777 (-3.05%) | View |
| 2024-01-31 2:08 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | BlackRock Inc. BLK | 8,417,524 5% | 7,343,033 (+683.40%) | View |
| 2024-01-16 4:18 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | MILLENNIUM MANAGEMENT LLC | 1,664,317 1% | -6,604,499 (-79.87%) | View |
| 2024-01-08 10:26 am Sale | 13G | X4 PHARMACEUTICALS INC XFOR | Empery Asset Management LP | 4,549,605 2.65% | -1,649,079 (-26.60%) | View |
| 2023-06-16 4:04 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | MILLENNIUM MANAGEMENT LLC | 8,268,816 5.2% | 8,268,816 (New Position) | View |
| 2023-05-26 3:03 pm Purchase | 13D | X4 PHARMACEUTICALS INC XFOR | Growth Equity Opportunities 18 VGE LLC | 15,742,792 9.99% | 3,605,999 (+29.71%) | View |
| 2023-02-14 5:24 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | ORBIMED ADVISORS LLC | 10,328,649 8.2% | 8,492,300 (+462.46%) | View |
| 2023-02-14 4:18 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | Point72 Asset Management L.P. | 913,242 1.3% | -719,962 (-44.08%) | View |
| 2023-02-14 11:26 am Sale | 13G | X4 PHARMACEUTICALS INC XFOR | Ikarian Capital LLC | 349,133 0.3% | -1,915,358 (-84.58%) | View |
| 2023-02-14 06:34 am Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | Bain Capital Life Sciences Fund L.P. | 12,202,510 11% | 9,315,968 (+322.74%) | View |
| 2023-02-13 5:51 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | BIOTECHNOLOGY VALUE FUND L P | 2,258,400 1.9% | -769,272 (-25.41%) | View |
| 2023-01-13 08:02 am Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | Empery Asset Management LP | 6,198,684 5.12% | 6,198,684 (New Position) | View |
| 2022-12-19 5:31 pm Purchase | 13D | X4 PHARMACEUTICALS INC XFOR | Growth Equity Opportunities 18 VGE LLC | 12,136,793 9.99% | 5,258,636 (+76.45%) | View |
| 2022-07-19 5:28 pm Purchase | 13D | X4 PHARMACEUTICALS INC XFOR | Growth Equity Opportunities 18 VGE LLC | 6,878,157 9.9% | 6,878,157 (New Position) | View |
| 2022-02-14 4:43 pm Sale | 13G | X4 PHARMACEUTICALS INC XFOR | Ikarian Capital LLC | 2,264,491 8.1% | -360,497 (-13.73%) | View |
| 2022-02-14 4:38 pm Purchase | 13G | X4 PHARMACEUTICALS INC XFOR | Point72 Asset Management L.P. | 1,633,204 5.8% | 132,961 (+8.86%) | View |